Who can administer
May be administered by registered competent doctor or nurse/midwife
Important information
- Consider IV to oral switch as soon as possible as excellent oral bioavailability (100%)
- There is no experience with administration of intravenous levetiracetam for periods greater than four days
- Avoid sudden withdrawal - suggest reduce at same rate as for dose increases
- See under 'Dose' for adjustments required in renal impairment (maintenance doses only)
- See local guidelines for Status Epilepticus
Available preparations
Keppra 500mg per 5mL vial
Levetiracetam 500mg per 5mL ampoule
Reconstitution
Already in solution
Draw up using a 5 micron filter needle (ampoule)
Dilute further prior to administration
Infusion fluids
Sodium chloride 0.9% or Glucose 5%
Methods of intravenous administration
Intermittent intravenous infusion
- Add required dose to 100mL of infusion fluid
- Administer over 15 minutes (but see below re rate in status epilepticus)
Dose in adults
Status Epilepticus (unlicensed ref 2,3)
Loading dose (Status Epilepticus)
- Give 60 mg/kg IV (to a maximum 4500 mg) infused over 10 minutes - see table below
- Flush the giving set with 25mL of infusion fluid at the same rate after the dose to ensure the full dose is administered
Status epilepticus: Loading doses |
Body weight (kg) |
Dose |
40 kg |
2,400mg |
50 kg |
3,000mg |
60 kg |
3,600mg |
70 kg |
4,200mg |
75 kg plus |
4,500mg |
Maintenance dose after loading doses (Status Epilepticus)
- Commence maintenance dose 10 to 14 hours after the loading dose
- If CrCl 50mL/min/1.73m2 or more: Give 1000mg twice daily
- (max 1500mg twice daily, higher doses of up to 30mg/kg twice daily may be used on ONGOING advice of neurologist)
- if CrCl less than 50mL/min/1.73m2 -See Renal dosage table below
Other Indications
Note: the doses below are as per SPC- this differs from the BNF in some cases
- Initial therapeutic dose:
- Give 500mg twice daily
- A lower initial dose of 250mg twice daily may be given based on an assessment of seizure reduction vs potential adverse effects. This can be increased to 500mg twice daily after two weeks
- Depending on the clinical response and tolerability, the daily dose can be increased up to 1500mg twice daily
- Dose changes can be made in 250mg or 500mg twice daily increases/decreases every two to four weeks
- Maximum dose: 1,500mg twice daily (but see also under Status epilepticus above)
Conversion from oral to IV therapy (for example if patient nil po)(ref 1)
- Maintain the same total daily dose and frequency of administration
- For example: 500mg twice daily orally, can be switched to 500mg twice daily by intravenous infusion.
Renal impairment in adult patients (maintenance doses)
CrCl (mL/min/1.73m2) |
Dose |
Frequency |
50 to 79 |
500 to 1000mg |
every 12 hours |
30 to 49 |
250 to 750mg |
every 12 hours |
less than 30 |
250 to 500mg |
every 12 hours |
Renal replacement therapy |
consult pharmacy or specialist text |
|
Hepatic impairment
- Give 50% dose reduction of the daily maintenance dose in severe hepatic impairment if the CrCl is less than 60ml/minute/1.73m2
Storage
Store below 250C
References
Keppra SPC February 2023
1: Injectable medicines guide, downloaded from Medusa 6th March 2024
2: Status epilepticus guideline, Walton Centre, NHS foundation trust, May 2020
3: GUH Status epilepticus guideline
Therapeutic classification
Antiepileptic